Pharmaceuticals, Biotechnology & Life Sciences

IQVIA’s share price climbs to the upper‑mid $230s, driven by a positive earnings outlook and a data‑driven clinical development strategy that blends real‑world evidence with molecular biology.

Sanofi’s Phase‑3 win for amlitelimab shows early, sustained efficacy in atopic dermatitis, offering a competitive entry into the growing AD biologics market and a strategic chance to capture market share before major patent expirations.

Qiagen’s share surge amid takeover buzz highlights its strong molecular‑diagnostics portfolio, CRISPR‑tech, and growth prospects in a consolidating market.

Takeda launches low‑IgA, ready‑to‑use GAMMAGARD LIQUID ERC in the U.S. to streamline PI therapy, cut admin costs, and outpace competitors with a strong IP moat.

Danaher’s rising institutional interest and robust margins show it can absorb Alabama’s new Medicaid checks while thriving under bundled payments and tech‑driven cost controls.

Short‑seller Kintbury ramps up Grifols stake, sparking debate on its future amid solid market backdrop.

Gilead’s Trodelvy + Keytruda combo shows a 32% OS boost for metastatic triple‑negative breast cancer, but with higher toxicity—what it means for investors, regulators, and payers.

Thermo Fisher Scientific’s strong earnings, strategic focus on high‑growth cell‑separation and CRISPR markets, disciplined capital allocation, and proactive M&A keep it a top institutional‑investor choice for long‑term life‑science growth.

Danaher’s 2026 stock steadiness hides growth from AI diagnostics and ESG‑focused products, plus supply‑chain resilience that could boost value.

Qiagen NV’s shares swing as rumors of a sale spread—find out why analysts are split and how a strategic deal could reshape the diagnostics market.